We have previously shown, in patients with allergic asthma 24or IgE‐mediated allergy to milk 28or peanut 29, that an increased omalizumab dose could further eliminate additional IgE‐ab and improve clinical symptoms not only from the lung but also from the nose, gastro‐intestinal tract, and dermis. The gene discussed is IGHE; the disease is allergic asthma.